Lorazepam Metabolism and Use in Patients with Liver Disease

Metabolic Pathway and Advantages

• Lorazepam is metabolized by the liver through direct glucuronide conjugation, without requiring oxidative metabolism pathways that are affected by liver disease, making it a suitable option for patients with hepatic impairment 1
• The glucuronidation pathway remains relatively preserved even in the setting of significant hepatic dysfunction, which makes lorazepam a preferred benzodiazepine in patients with liver disease 2

Clinical Implications and Recommendations

• For patients with liver disease requiring benzodiazepines, lorazepam is recommended over long-acting benzodiazepines, according to the French Association for the Study of the Liver, due to its minimal impact on liver disease 2
• The French Association for the Study of the Liver specifically recommends short-acting benzodiazepines like lorazepam for patients with decompensated liver disease 2

Important Considerations and Precautions

• Parenteral formulations of lorazepam contain propylene glycol as a diluent, which can cause toxicity in ICU patients, manifesting as metabolic acidosis and acute kidney injury, with total daily IV doses as low as 1 mg/kg causing toxicity 1
• The elimination half-life and duration of clinical effect of lorazepam are increased in patients with renal failure 1